These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34638085)

  • 1. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry.
    Pavlidis N; Rassy E; Vermorken JB; Assi T; Kattan J; Boussios S; Smith-Gagen J
    Cancer Epidemiol; 2021 Dec; 75():102045. PubMed ID: 34638085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
    Liao CI; Chow S; Chen LM; Kapp DS; Mann A; Chan JK
    Gynecol Oncol; 2018 May; 149(2):318-323. PubMed ID: 29514737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis.
    Jordan SJ; Green AC; Whiteman DC; Moore SP; Bain CJ; Gertig DM; Webb PM; ;
    Int J Cancer; 2008 Apr; 122(7):1598-603. PubMed ID: 18058817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960-2014: A population-based cohort study.
    Leandersson P; Hogberg T; Dickman PW; Malander S; Borgfeldt C
    BMC Cancer; 2021 Apr; 21(1):465. PubMed ID: 33902507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis.
    Somasegar S; Reddy RA; Chow S; Dorigo O; Renz M; Karam A
    Gynecol Oncol; 2024 May; 184():190-197. PubMed ID: 38330833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
    Martin JY; Urban RR; Liao JB; Goff BA
    J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities - a systematic review.
    Sørensen RD; Schnack TH; Karlsen MA; Høgdall CK
    Gynecol Oncol; 2015 Mar; 136(3):571-81. PubMed ID: 25615934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
    Cheng M; Lee HH; Chang WH; Lee NR; Huang HY; Chen YJ; Horng HC; Lee WL; Wang PH
    Int J Environ Res Public Health; 2019 Nov; 16(23):. PubMed ID: 31795359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004.
    Goodman MT; Shvetsov YB
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):132-9. PubMed ID: 19124490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
    Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
    Herzog TJ; Monk BJ; Rose PG; Braly P; Hines JF; Bell MC; Wenham RM; Secord AA; Roman LD; Einstein MH; Drake RD; Childs BH
    Gynecol Oncol; 2014 Mar; 132(3):517-25. PubMed ID: 24476788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review.
    Pentheroudakis G; Pavlidis N
    Crit Rev Oncol Hematol; 2010 Jul; 75(1):27-42. PubMed ID: 19897383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
    J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
    Webber K; Friedlander M
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():126-138. PubMed ID: 28027849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
    Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
    Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
    Taylor SE; Chu T; Elvin JA; Edwards RP; Zorn KK
    Gynecol Oncol; 2020 Jan; 156(1):32-37. PubMed ID: 31739991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Schwandt A; von Gruenigen VE; Wenham RM; Frasure H; Eaton S; Fusco N; Fu P; Wright JJ; Dowlati A; Waggoner S
    Invest New Drugs; 2014 Aug; 32(4):729-38. PubMed ID: 24619298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.